<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0606222136
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2008
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RHOPHYLAC 300MCG-2ML SOL. FOR INJ.IN PFS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ANTI-D (RH0) IMMUNOGLOBULIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Injection Syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        228.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CSL BEHRING" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CSL BEHRING
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            CSL BEHRING
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J06BB01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>29 This medicine is a ready-to-use solution for intravenous or intramuscular administration provided in a pre-30 filled syringe. The solution contains proteins isolated from the human blood plasma that belong to the class 31 of immunoglobulins also called antibodies produced by the human immune system. The active ingredient 32 of Rhophylac is the specific antibody called anti-D immunoglobulin. 33<br />CSL Behring CCPIL<br />Rhophylac, Human Anti-D Immunoglobulin<br />Version 3.0 Revision Date 21-AUG-2019<br />This antibody works against the Rhesus factor type D (abbreviated Rh(D)), 34 a special characteristic of 35 human red blood cells. People who carry the Rhesus factor type D are called Rh(D) positive. Those who do 36 not carry the Rhesus factor type D are called Rh(D) negative.</p><p>38 What anti-D immunoglobulin is 39 When a Rh(D) negative person receives Rh(D) positive blood, her/his immune system will recognise the 40 Rh(D) positive red blood cells as &ldquo;foreign&rdquo; to her/his body, and will attempt to destroy them. For this 41 purpose, the immune system will build the specific antibody against Rhesus factor type D. This process is 42 called &ldquo;immunisation&rdquo; and it usually takes some time (2 to 3 weeks). Consequently, the Rh(D) positive red 43 blood cells will not be destroyed upon the first contact, and no signs or symptoms are usually seen then. 44 But when the same Rh(D) negative person receives Rh(D) positive blood a second time, the specific 45 antibody will be &ldquo;ready at hand&rdquo; and destroy the foreign Rh(D) positive red blood cells immediately. 46<br />47 How Rhophylac works 48 If a Rh(D) negative person is given a sufficient amount of human anti-D immunoglobulin, the 49 isoimmunisation against Rhesus factor type D can be prevented. To achieve this, treatment with 50 Rhophylac should commence before or early enough after the first contact to Rh(D) positive red blood 51 cells. The anti-D immunoglobulins contained in Rhophylac will then destroy the foreign Rh(D) 52 positive red blood cells immediately. Thus, the person&#39;s immune system will not be prompted to build-up 53 its own antibodies. 54<br />55<br />56 What Rhophylac is used for 57 This medicine is used in the following situations: 58<br />59 A) You are a Rh(D) negative pregnant woman, who carries a Rh(D) positive baby. 60 In this special situation you may be immunised by the Rh(D) positive red blood cells from your baby 61 passing over into your own blood circulation. If this happens, the first baby is usually not affected and fully 62 healthy. However in your next Rh(D) positive baby, your antibodies would destroy the baby&#39;s Rh(D) 63 positive red blood cells during pregnancy. This may lead to complications in the development of your next 64 baby, including its possible death. 65 For that reason, you may receive Rhophylac: 66 &bull; when you carry or have just delivered a Rh(D) positive baby;<br />CSL Behring CCPIL<br />Rhophylac, Human Anti-D Immunoglobulin<br />Version 3.0 Revision Date 21-AUG-2019<br />&bull; when you lose a Rh(D) positive baby (intrauterine fetal death, miscarriage, 67 threatened miscarriage 68 or abortion); 69 &bull; when your pregnancy is severely complicated (ectopic pregnancy or pregnancy with a non-viable 70 fertilized egg (hydatidiform mole)); 71 &bull; when it is likely that your baby&#39;s Rh(D) positive red blood cells have passed over into your own 72 blood circulation (transplacental haemorrhage resulting from antepartum haemorrhage). This may, 73 for example, happen when you experience vaginal bleedings during pregnancy; 74 &bull; when your doctor needs to perform testing methods for fetal deformities (amniocentesis, chorionic 75 biopsy, cordocentesis); 76 &bull; when your doctor or midwife needs to try moving the baby from outside (e.g., external version of 77 the baby or other obstetric manipulative procedures); 78 &bull; when you have an accident hurting your stomach or gut (abdominal trauma). 79<br />80 This medicine is used also if you are a Rh(D) negative pregnant woman and it is not known if your baby is 81 Rh(D) positive. 82<br />83 B) You are a Rh(D) negative adult, child or adolescent (0 to 18 years), who has accidentally 84 received infusions (transfusions) of Rh(D) positive blood or other preparations containing Rh(D) 85 positive red blood cells like &ldquo;platelet concentrate&rdquo; (mismatched transfusion).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>90 Do not use Rhophylac 91 &bull; If you are allergic (hypersensitive) to human immunoglobulins or any of the other ingredients 92 (excipients) of this medicine (listed in section 6). 93 Tell your doctor or healthcare professional prior to treatment about any medicine which you have 94 not well tolerated earlier. 95 &bull; You must not receive injections into a muscle, if you suffer from a severe reduction in the number 96 of platelets (severe thrombocytopenia) or any other blood clotting disorder. 97 Tell your doctor or healthcare professional prior to treatment if this applies to you. In this case this 98 medicine may be given to you only by injection into a vein.</p><p>100 Warnings and Precautions 101 Talk to your doctor or healthcare professional before you are given Rhophylac. 102 &bull; For protecting Rh(D) negative woman after delivery of a Rh(D) positive baby, this medicine is 103 always given to the mother, not to the new-born baby. 104 &bull; This medicine is not intended for use in Rh(D) positive persons, nor for individuals already 105 immunised to Rh(D) antigen. 106<br />107 When stopping the administration may be required 108 &bull; Rhophylac may trigger hypersensitivity (allergic) reactions. In rare cases, allergic reactions such as 109 sudden fall in blood pressure or shock may occur even if you have previously received human 110 immunoglobulins and had tolerated them well (see also section 4 &ldquo;Possible side effects&rdquo;). 111 Tell your doctor or healthcare professional immediately if such reactions occur. He or she will then stop 112 the administration of the product and treat you depending on the nature and severity of the side effect. 113<br />114 Your doctor or healthcare professional will take special care 115 &bull; If you have low levels of the IgA type immunoglobulins (IgA deficiency), you are more likely to 116 experience a hypersensitivity reaction. 117 Tell your doctor or healthcare professional if you have low levels of IgA. He or she will then very 118 thoroughly weigh the benefit of treatment with this medicine against the increased risk of 119 hypersensitivity reactions. 120 &bull; If you are treated with Rhophylac after a mismatched transfusion, you may receive quite a large 121 amount of this medicine (up to 3000 micrograms, equivalent to 20 ml or 10 syringes). In this case 122 a so called haemolytic reaction occurs. This results from the intended destruction of the foreign 123 Rh(D) positive red blood cells. For this reason your doctor or healthcare professional will monitor 124 you closely and may need to do special blood tests. 125 &bull; If your body mass index (BMI) is greater or equal to 30 (calculated by dividing your body mass by 126 the square of your height), the injection of Rhophylac into a muscle may be not fully effective. In 127 this case, your doctor or healthcare professional should rather consider injecting this medicine into 128 a vein.</p><p>130 Pathogen safety 131 This medicine is made from human blood plasma. This is the liquid part of the blood. When medicines are 132 made from human blood or plasma, certain measures are put in place to prevent infections being passed on<br />CSL Behring CCPIL<br />Rhophylac, Human Anti-D Immunoglobulin<br />Version 3.0 Revision Date 21-AUG-2019<br />to patients. T133 hese measures include:</p><p>134 &bull; careful selection of blood and plasma donors to make sure those at risk of carrying infections are 135 excluded, 136 &bull; the testing of each donation and pools of plasma for signs of virus/infections, 137 &bull; the inclusion of steps in the processing of the blood or plasma that can inactivate or remove 138 viruses. 139 Despite these measures, when medicines prepared from human blood or plasma are administered, the 140 possibility of passing on infection cannot be totally excluded. This also applies to any unknown or 141 emerging viruses or other types of infections. 142 The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus 143 (HIV, the AIDS virus), hepatitis B virus and hepatitis C virus (liver inflammation). The measures taken 144 may be of limited value against non-enveloped viruses such as hepatitis A virus and parvovirus B19. 145<br />146 Immunoglobulins have not been associated with hepatitis A or parvovirus B19 infections possibly 147 because the antibodies against these infections, which are contained in the product, are protective. 148<br />149 It is strongly recommended that every time you receive a dose of Rhophylac the name and batch 150 number of the product are recorded in order to maintain a record of the batches used. 151<br />152 Other medicines and Rhophylac 153<br />154 Tell your doctor or healthcare professional if you are taking, have recently taken or might take any 155 other medicines. This also applies to medicines obtained without a prescription.</p><p>157 Vaccinations 158 This medicine may impair the efficacy of vaccinations with live virus vaccines, for example against 159 measles, mumps, rubella (German measles) or varicella. Such vaccinations should therefore not be given 160 for 3 months after you were last given Rhophylac. 161 Tell your doctor or healthcare professional prior to treatment if you have just had a vaccination within 162 the last 2 to 4 weeks. Inform also your vaccinating doctor after the treatment. He or she can then plan 163 to check the efficacy of your vaccination.</p><p>165 Blood tests<br />CSL Behring CCPIL<br />Rhophylac, Human Anti-D Immunoglobulin<br />Version 3.0 Revision Date 21-AUG-2019<br />After you were given this medicine, the results of some blood tests (serological 166 testing) may be altered 167 for a certain period of time. If you are a mother having received this medicine before delivery, the 168 results of some blood tests in your new-born baby may also be affected. 169 Tell your doctor or healthcare professional that you were treated with Rhophylac if you or your new-170 born baby have any blood tests. 171<br />172 Pregnancy, breastfeeding and fertility 173 This medicinal product is used in pregnancy and postpartum period. There are no known negative 174 effects on the course of pregnancy and/or the new born. 175 This medicinal product can be used during lactation. 176<br />177 Driving and using machines 178 There is no evidence of any adverse effects on the ability to drive or to operate machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>182 Dosage 183 This medicine will be injected by your doctor or healthcare professional into a muscle or directly into a 184 vein. Your doctor will decide how much Rhophylac you should receive and which is the appropriate route 185 of administration. For example, if your body mass index (BMI) is greater or equal to 30, he/she should 186 rather consider injecting this medicine directly into a vein (see also section 2). 187<br />188 Other instructions for use 189 &bull; The syringe should be brought to room temperature (25 &deg;C) before use. 190 &bull; One syringe should be used for one patient only (even if product is left over). 191 &bull; You should be observed for at least 20 minutes after having received Rhophylac. 192<br />193 If you have any further questions on the use of this medicine, please ask your doctor or healthcare 194 professional.</p><p>If you receive more Rhophylac than you should 197 Consequences of an overdosage are not known.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>202 Like all medicines, this medicine can cause side effects, although not everybody gets them. Such side 203 effects may occur even if you previously received human immunoglobulins and tolerated them well. 204<br />205 If you are given this medicine into a muscle, you may feel local pain and tenderness at the injection site. 206<br />207 Side effects observed in controlled clinical studies are presented in order of decreasing frequency: 208 The following side effects were uncommon (affects 1 to 10 users in 1000): 209 &bull; headache 210 &bull; skin reaction 211 &bull; redness of the skin (erythema) 212 &bull; itching (pruritus) 213 &bull; fever 214 &bull; generally feeling unwell (malaise) 215 &bull; chills (shivering) 216<br />217 The following side effects were rare (affects 1 to 10 users in 10,000): 218 &bull; allergic reactions 219 &bull; anaphylactic shock 220 &bull; rapid heartbeat or pulse rate (tachycardia) 221 &bull; low blood pressure (hypotension) 222 &bull; difficulty in breathing (dyspnoea) 223 &bull; nausea 224 &bull; vomiting 225 &bull; joint pain (arthralgia) 226 &bull; reactions at the injection site.</p><p>228 In isolated cases (post-marketing experience) breakdown of red blood cells (severe intravascular 229 haemolysis) has been observed in treatment with Rhophylac. Intravascular haemolysis can lead to 230 clinically compromising reduction in red blood cells (anaemia) and multi-system organ failure, including<br />CSL Behring CCPIL<br />Rhophylac, Human Anti-D Immunoglobulin<br />Version 3.0 Revision Date 21-AUG-2019<br />severe respiration difficulty (acute respiratory distress syndrome). Haemolysis r231 esulting in death has been 232 reported.</p><p>234 Reporting of side effects 235 If you get any side effects, talk to your doctor or healthcare professional. This includes any possible side 236 effects not listed in this leaflet. By reporting side effects you can help provide more information on the 237 safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>238 5. How to store Rhophylac 239 &bull; Store in a refrigerator (+2 to +8 &deg;C). 240 &bull; Do not freeze. 241 &bull; Do not use this medicine after the expiry date which is stated on the outer carton and the syringe 242 label after EXP. The expiry date refers to the last day of that month. 243 &bull; Shelf life is 36 months. 244 &bull; Keep out of the sight and reach of children. 245 &bull; Keep the syringe in the outer carton (in its sealed plastic pack) in order to protect from light. 246 &bull; Do not use this medicine if you notice that the solution is cloudy or has deposits. 247 &bull; Do not throw away any medicines via wastewater or household waste. 248 Ask your pharmacist how to throw away medicines you no longer use. These measures will help 249 protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>255 Active substance 256 Human anti-D immunoglobulin. 257 Rhophylac 300 contains a maximum of 60 mg human plasma proteins per pre-filled syringe 258 (2 mL), of which 20 mg is albumin as stabiliser. At least 95% of the other plasma proteins consist 259 of IgG. 260 The IgA content is below the detection limit of 10 mcg/pre-filled syringe (2 mL). 261 Excipients 262 Human albumin 20 mg/pr-efilled syringe (2 mL, as stabiliser), glycine, sodium chloride maximum 263 of 0.5 mmol sodium per pre-filled syringe), acetic acid, water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                265 Rhophylac 300 is provided in a pre-filled glass syringe with 2 ml of ready-to-use sterile solution, 266 containing 1500 IU (300 micrograms) of anti-D immunoglobulin.
hophylac 300 is a clear, colourless to pale yellow immunoglobulin s267 olution. The solution is 268 slightly hypertonic. 269 Rhophylac is available in single packs containing 1 pre-filled syringe and 1 injection needle, both packed 270 in one blister pack (a clear plastic container sealed with a paper foil).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>273 CSL Behring AG 274 Wankdorfstr. 10 275 3014 Bern 276 Switzerland</p><p>278 To report any side effect(s): 279 Saudi Arabia: 280 The National Pharmacovigilance Centre (NPC): 281 SFDA Call Center: 19999 282 E-mail: npc.drug@sfda.gov.sa 283 Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ھذا الدواء ھو محلول جاھز للاستخدام للحقن عبر الورید أو العضل ومتوفر في محقنة معبأة مسبقًا. یحتوي المحلول على بروتینات تم 28 فصلھا من بلازما الدم البشریة تنتمي إلى فئة الغلوبولین المناعي التي تسمى أیضًا الأجسام المضادة التي ینتجھا جھاز المناعة البشري. 29 المادة الفعالة في روفیلاك ھي الجسم المضاد المحدد المسمى الغلوبولین المناعي المضاد ل د .<br />30د) ، وھذا من خصائص خلایا الدم الحمراء )Rh) 31 یعمل ھذا الجسم المضاد ضد عامل الریسوس من النوع د (یُشار إلیھ باختصار باسمد) موجب. یُطلق على أولئك الذین لا یحملون عامل )Rh 32 البشریة. یُطلق على الأشخاص الذین یحملون عامل الریسوس من النوع د اسمد). )Rh 33 الریسوس من النوع د سالب</p><p>ما ھو الغلوبولین المناعي المضاد ل د د)، سیتعرف جھازه المناعي على خلایا الدم الحمراء الإیجابیة لعامل )Rh د) سلبي دمًا إیجابیًا لعامل)Rh 36 عندما یتلقى شخص ذو عاملد) على أنھا &quot;غریبة&quot; على جسمھ، وسیحاول إتلافھا. ولھذا الغرض، سیبني جھاز المناعة الجسم المضاد المحدد ضد عامل الریسوس )Rh 3738 من النوع د. وتسمى ھذه العملیة &quot;التحصین&quot; وعادة ما تستغرق بعض الوقت (من 2 إلى 3 أسابیع). وبالتالي، لن تُتلف خلایا الدم الحمراء د) عند الاتصال الأول، وعادةً لا تظھر أي علامات أو أعراض فیما بعد. ولكن عندما یتلقى نفس الشخص ذو عامل )Rh 39 الإیجابیة لعاملد) مرة ثانیة، سیكون الجسم المضاد المحدد &quot;جاھزًا للاستعمال&quot; ویتلف خلایا الدم الحمراء الغریبة )Rh د) السلبي دمًا إیجابیًا لعامل)Rh 40د) على الفور . )Rh 41 الإیجابیة لعامل<br />4243 كیف یعمل دواء روفیلا ك د) سلبي كمیة كافیة من الغلوبولین المناعي البشري المضاد ل د، فیمكن الوقایة من المناعة المتماثلة ضد )Rh 44 إذا أعُطي شخص ذو عامل45 عامل الریسوس من النوع د. ولتحقیق ذلك، یجب أن یبدأ العلاج باستخدام روفیلاك قبل أو في وقت مبكر بما یكفي بعد أول اتصال بخلایا Rh د). ثم سیُتلف الغلوبولین المناعي المضاد ل د الموجود في روفیلاك، خلایا الدم الحمراء الإیجابیة ل)Rh 46 الدم الحمراء الإیجابیة لعامل47 (د) الغریبة، على الفور. وبالتالي، لن یُطلب من الجھاز المناعي للشخص تكوین الأجسام المضادة الخاصة بھ .</p><p>دواعي استعمال روفیلا ك 51 یُستخدم ھذا الدواء في الحالات التالیة :<br />52د) إیجابي . )Rh د) سلبي، تحمل طفلا ذي عامل)Rh 53 أ) إذا كنتِ امرأة حامل ذات عاملد) من طفلكِ والتي تنتقل إلى دورتك الدمویة. إذا )Rh 54 في ھذه الحالة الخاصة، قد تُحصنین بواسطة خلایا الدم الحمراء الإیجابیة لعاملد)، ستتلف الأجسام )Rh 55 حدث ذلك، فعادةً لا یتأثر الطفل الأول ویحظى بصحة جیدة. ومع ذلك، في حالة طفلكِ التالي الإیجابي لعاملد) لدى الطفل خلال الحمل. قد یؤدي ذلك إلى مضاعفات في نمو طفلكِ التالي، بما في )Rh 56 المضادة خلایا الدم الحمراء الإیجابیة لعامل57 ذلك احتمال وفاتھ . 58 لھذا السبب، فقد تتلقین روفیلاك: د) إیجابي ؛ )Rh &bull; عندما تحملین أو إذا ولدتِ للتو طفلاً ذا عامل59<br />د) إیجابي (موت الجنین داخل الرحم أو الإجھاض أو التعرض لخطر الإجھاض أو الإسقَاط)؛ )Rh &bull; عندما تفقدین طفلا ذا عامل60<br />&bull; عندما یكون حملكِ معقدًا للغایة (حمل خارج الرحم أو حمل مع بویضة مخصبة غیر قابلة للحیاة (الحمل الرحوي)) ؛ 61<br />د) لدى طفلكِ قد انتقلت إلى دورتكِ الدمویة (نزیف )Rh 62 &bull; عندما یكون من المحتمل أن تكون خلایا الدم الحمراء الإیجابیة لعاملعبر المشیمة ناتج عن نزیف ما قبل الولادة). قد یحدث ھذا، على سبیل المثال، عندما تعانین من نزیف مھبلي خلال الحمل ؛ 63<br />&bull; عندما یحتاج طبیبك إلى إجراء طرق اختبار تشوھات الجنین (بزل السلى، الخزعة المشیمائیة، بزل الحبل السري)؛ 64<br />65 &bull; عندما یحتاج طبیبكِ أو القابلة إلى محاولة نقل الطفل من الخارج (على سبیل المثال، تغییر وضعیة الطفل أو إجراءات مناورة التولید الأخرى) ؛ 66<br />&bull; عندما تتعرضین لحادث یؤذي معدتك أو أمعائك (رضح في البطن) .</p><p>د) لدى طفلكِ إیجابیًا . )Rh د) سلبي ومن غیر المعروف ما إذا كان عامل)Rh 69 یُستخدم ھذا الدواء أیضًا إذا كنتِ امرأة حامل ذات عامل</p><p>د) سلبي (حتى 18 عامًا)، تلقیت عن طریق الخطأ تسریبات (عملیات نقل دم) )Rh 71 ب) أنت شخص بالغ أو طفل أو مراھق ذو عامل د) مثل &quot;مركز الصفائح الدمویة&quot; (نقل دم )Rh د) أو مستحضرات أخرى تحتوي على خلایا دم حمراء إیجابیة لعامل)Rh 72 إیجابیة لعامل73 غیر متطابق)</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستخدم روفیلا ك 79 &bull; إذا كنت تعاني من حساسیة (فرط الحساسیة) تجاه الغلوبولین المناعي البشري أو أي من المكونات (السواغات) الأخرى لھذا .(الدواء (المدرجة في القسم 680<br />أخبر طبیبك أو اختصاصي الرعایة الصحیة المتابع لك قبل العلاج بأي دواء لم تتحملھ جیدًا في السابق.  8182 &bull; یجب ألا تتلقى حقنًا في العضلة، إذا كنت تعاني من انخفاض شدید في عدد الصفائح الدمویة (قلة الصفیحات الشدیدة) أو أي اضطراب آخر في تخثر الدم . 83<br />أخبر طبیبك أو اختصاصي الرعایة الصحیة المتابع لك قبل العلاج إذا كان ھذا ینطبق علیك. في ھذه الحالة، لا یمكن إعطاؤك ھذا  8485 الدواء إلا عبر الحقن في الورید .<br />8687 التحذیرات والاحتیاطا ت تحدث إلى طبیبك أو اختصاصي الرعایة الصحیة المتابع لك قبل أن تُعطى روفیلاك .  88د)، یُعطى ھذا الدواء دائمًا للأم، ولیس للطفل )Rh د) الإیجابي بعد ولادة طفل إیجابي لعامل)Rh 89 &bull; لحمایة المرأة ذات عاملحدیث الولادة . 90<br />د) الإیجابي، ولا للأفراد الذین تم تحصینھم بالفعل ضد )Rh 91 &bull; ھذا الدواء غیر مخصص للاستخدام مع الأشخاص ذوي عاملد). )Rh مستضد92<br />9394 عند إیقاف الإعطاء، قد تكون ھناك حاج ة 95 &bull; قد یحفّز روفیلاك ردود فعل فرط الحساسیة (حساسیة). في حالات نادرة، قد تحدث ردود فعل تحسسیة مثل الانخفاض المفاجئ 96 في ضغط الدم أو الصدمة حتى إذا كنت قد تلقیت الغلوبولین المناعي البشري من قبل وتحمّلتھ جیدًا (انظر أیضًا القسم 4 &quot;الآثار الجانبیة المحتملة&quot;) . 97<br />أخبر طبیبك أو اختصاصي الرعایة الصحیة على الفور إذا حدثت ردود الفعل ھذه. حینئذ، سیوقف إعطاء المنتج ویعالجك بناءً على  9899 طبیعة الأثر الجانبي وشدتھ .</p><p>101 سیولي طبیبك أو أخصائي الرعایة الصحیة رعایة خاص ة فمن المرجح أن ،(A نقص الغلوبولین المناعي) IgA 102 &bull; إذا كنت تعاني من مستویات منخفضة من الغلوبولین المناعي من النوعتعاني من رد فعل فرط الحساسیة . 103<br />بعد ذلك، سیوازن بدقة .A أخبر طبیبك أو اختصاصي الرعایة الصحیة إذا كنت تعاني من انخفاض مستویات الغلوبولین المناعي 104105 شدیدة بین فائدة العلاج بھذا الدواء وخطر تفاعلات فرط الحساسیة المتزاید. 106 &bull; إذا عولجت بعقار روفیلاك بعد نقل دم غیر متطابق، فقد تتلقى كمیة كبیرة جدًا من ھذا الدواء (حتى 3000 میكروغرام، أي ما 107 یعادل 20 مل أو 10 محاقن). في ھذه الحالة یحدث ما یسمى بالتفاعل الانحلالي. ینتج ھذا عن الإتلاف المقصود لخلایا الدم د). لھذا السبب، سیراقبك طبیبك أو اختصاصي الرعایة الصحیة عن كثب وقد یحتاج إلى )Rh 108 الحمراء الغریبة الإیجابیة لعاملإجراء اختبارات دم خاصة . 109<br />أكثر من أو یساوي 30 (یتم حسابھ بقسمة كتلة جسمك على مربع طولك)، فقد لا یكون حقن (BMI) 110 &bull; إذا كان مؤشر كتلة جسمكروفیلاك في العضل فعالا تمامًا. في ھذه الحالة، یجب أن یفكر طبیبك أو اختصاصي الرعایة الصحیة في حقن ھذا الدواء في الورید . 111<br />112113 سلامة مسببات الأمرا ض 114 ھذا الدواء مصنوع من بلازما الدم البشریة. ھذا ھو الجزء السائل من الدم. عندما تُصنع الأدویة من الدم البشري أو البلازما، تُتخذ تدابیر 115 مُعیَّنة لمنع انتقال العدوى إلى المرضى. وتشمل ھذه التدابیر: &bull; الاختیار الدقیق للمتبرعین بالدم والبلازما للتأكد من استبعاد المعرضین لخطر الإصابة بالعدوى، 116<br />&bull; اختبار كل تبرعات وتجمیعات البلازما بحثًا عن علامات الفیروس/العدوى ، 117<br />&bull; إدراج خطوات في معالجة الدم أو البلازما یمكنھا تعطیل أو إزالة الفیروسات . 118<br />119 وعلى الرغم من ھذه التدابیر، فعند إعطاء الأدویة المحضرة من الدم أو البلازما البشریة، لا یمكن استبعاد إمكانیة نقل العدوى تمامًا. 120 وینطبق ھذا أیضًا على أي فیروسات غیر معروفة أو ناشئة أو أنواع أخرى من العدوى . فیروس الإیدز)، وفیروس التھاب الكبد ،HIV) 121 تعتبر التدابیر المتخذة فعالة بالنسبة للفیروسات المغلفة مثل فیروس نقص المناعة البشریةقد تكون التدابیر المتخذة ذات قیمة محدودة ضد الفیروسات غیر المغلفة مثل فیروس .(HCV) وفیروس التھاب الكبد س (HBV) 122 ب . B19</p><p>ربما لأن الأجسام المضادة لھذه العدوى، الموجودة في B19 لم ترتبط الغلوبولینات المناعیة بعدوى التھاب الكبد أ أو الفیروس الصغیر 19126 المنتج، تكون وقائیة .<br />127یُوصى بشدة بتسجیل اسم ورقم دفعة المنتج في كل مرة تتلقى فیھا جرعة من دواء روفیلاك من أجل الاحتفاظ بسجل للدفعات المستخدمة .  128<br />129130 الأدویة الأخرى وعقار روفیلا ك<br />131أخبر طبیبك أو أخصائي الرعایة الصحیة إذا كنت تتناول، أو تناولت مؤخرًا، أو قد تتناول أي أدویة أخرى. وینطبق ھذا أیضًا  132133 على الأدویة التي یتم الحصول علیھا من دون وصفة طبیة</p><p>اللقاحا ت 136 قد یضعف ھذا الدواء من فعالیة اللقاحات التي تحتوي على لقاحات الفیروس الحي، على سبیل المثال ضد الحصبة والنكاف والحمیراء 137 (الحصبة الألمانیة) أو الحُماق. لذلك یجب عدم إعطاء ھذه اللقاحات لمدة 3 أشھر بعد آخر مرة تم إعطاؤك فیھا روفیلاك . أخبر طبیبك أو اختصاصي الرعایة الصحیة المتابع لك قبل العلاج إذا كنت قد تلقیت للتو لقاحًا خلال الأسبوعین إلى الأربعة أسابیع  138139 الماضیة. أبلغ أیضًا طبیبك الذي یعطیك التطعیم بعد العلاج. ویمكنھ بعد ذلك التخطیط للتحقق من فعالیة لقاحك .<br />140141 اختبارات الد م 142 بعد إعطائك ھذا الدواء، قد یتم تغییر نتائج بعض اختبارات الدم (الاختبارات السیرولوجیة) لفترة معینة من الوقت. إذا كنتِ أمًا قد 143 تلقیتِ ھذا الدواء قبل الولادة، فقد تتأثر أیضًا نتائج بعض اختبارات الدم لدى طفلكِ حدیث الولادة . أخبري طبیبكِ أو اختصاصي الرعایة الصحیة المتابع لكِ بأنكِ قد عولجتِ باستخدام روفیلاك إذا كنتِ أنتِ أو طفلكِ حدیث الولادة  144145 تخضعین لأي اختبارات دم .<br />146147 الحمل والرضاعة الطبیعیة والخصوب ة 148 یُستخدم ھذا المنتج الدوائي في فترة الحمل وما بعد الولادة. ما من تأثیرات سلبیة معروف ة 149 تؤثر في مسار الحمل و/أو الطفل حدیث الولادة . 150 یمكن استخدام ھذا المنتج الدوائي خلال الرضاعة .<br />151152 القیادة واستخدام الآلا ت 153 ما من دلیل على أي تأثیرات سلبیة في القدرة على القیادة أو تشغیل الآلات .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>157 الجرعة 158 سیحقن طبیبك أو اختصاصي الرعایة الصحیة ھذا الدواء في العضل أو في الورید مباشرةً. سیقرر طبیبكِ كمیة روفیلاك التي یجب أن أكثر من أو یساوي 30، فیجب أن (BMI) 159 تحصل علیھا وما الطریق المناسبة للإعطاء. على سبیل المثال، إذا كان مؤشر كتلة جسمك .(160 یفكر في حقن ھذا الدواء مباشرةً في الورید (انظر أیضًا القسم 2<br />161162 تعلیمات الاستخدام الأخرى &bull; یجب ترك المحقنة في درجة حرارة الغرفة (25 درجة مئویة) قبل الاستخدام . 163<br />&bull; یجب استخدام محقنة واحد ة لمریض واح د فقط (حتى لو تبقىّ المنتج) . 164<br />&bull; یجب أن تخضع للملاحظة مدة 20 دقیقة على الأقل بعد تلقي روفیلاك . 165<br />166167 إذا راودتك أي أسئلة أخرى حول استخدام ھذا الدواء، فیُرجى طرحھا على طبیبك أو اختصاصي الرعایة الصحیة المتابع لك .</p><p>إذا تلقیت جرعة من روفیلاك أكثر مما ینبغ ي 170 عواقب الجرعة الزائدة غیر معروفة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>175 مثل جمیع الأدویة، قد یسبب ھذا الدواء آثارًا جانبیة، على الرغم من أنھا لا تصیب الجمیع. قد تحدث ھذه الآثار الجانبیة حتى إذا كن ت قد 176 تلقیت الغلوبولین المناعي البشري من قبل وتحملتھ جیّدًا .<br />177178 إذا أُعطیت ھذا الدواء في العضل، فقد تشعر بألم وإیلام موضعي في موضع الحقن .<br />179180 تُعرض الآثار الجانبیة التي تمت ملاحظتھا في الدراسات السریریة الخاضعة للمراقبة بترتیب معدل التكرار المتناقص : :(181 كانت الآثار الجانبیة التالیة غیر شائعة (تؤثر في 1 إلى 10 مستخدمین من كل 1000&bull; صدا ع 182<br />&bull; رد فعل جلد ي 183<br />&bull; احمرار الجلد (حمامي ) 184<br />&bull; حكة 185<br />&bull; الحمى 186<br />&bull; الشعور بتوعك عمومًا (الإعیاء ) 187<br />&bull; قشعریرة (ارتجاف )</p><p>190 كانت الآثار الجانبیة التالیة نادرة (تؤثر في مستخدم واحد إلى 10 مستخدمین من بین كل 10000 مستخدم): &bull; ردود فعل تحسسی ة 191<br />&bull; صدمة تأقی ة 192<br />&bull; سرعة نبضات القلب أو معدل النبض (تسارع القلب ) 193<br />&bull; انخفاض ضغط الدم (ضغط دم منخفض ) 194<br />&bull; صعوبة في التنفس (ضیق التنفس ) 195<br />&bull; غثیان 196<br />&bull; تقیؤ 197<br />&bull; ألم المفاصل (ألم مفصلي ) 198<br />&bull; ردود فعل في موضع الحقن .</p><p>ف ي حالات معزول ة (تجربة ما بعد التسویق)، لوحظ تحلل خلایا الدم الحمراء (انحلال دموي شدید داخل الأوعیة الدمویة) عند العلاج بعقار 202 روفیلاك. قد یؤدي انحلال الدم داخل الأوعیة الدمویة إلى انخفاض سریري في خلایا الدم الحمراء (فقر الدم) وفشل أعضاء متعددة الأجھز ة، بما 203 في ذلك صعوبة التنفس الشدیدة (متلازمة الضائقة التنفسیة الحادة). تم الإبلاغ عن انحلال الدم الذي یؤدي إلى الوفاة .<br />204205 الإبلاغ عن الآثار الجانبی ة 206 إذا ظھرت علیك أي آثار جانبیة، فتحدث إلى طبیبك أو أخصائي الرعایة الصحیة. ویشمل ذلك أي آثار جانبیة مُحتمَلة غیر مُدرَجة في ھذه 207 النشرة. بالإبلاغ عن الآثار الجانبیة، یمكنك المساعدة في تقدیم مزید من المعلومات حول سلامة ھذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یحُفَظ في الثلاجة (+2 درجة إلى +8 درجة مئویة) . 209<br />&bull; لا ینبغي تجمیده في الفریزر . 210<br />یشیر .EXP 211 &bull; لا تستخدم ھذا الدواء بعد تاریخ انتھاء الصلاحیة المُسجّل على العلبة الكرتونیة الخارجیة وملصق المحقنة بعد كلمةتاریخ انتھاء الصلاحیة إلى الیوم الأخیر من ذلك الشھر . 212<br />&bull; تبلغ مدة الصلاحیة 36 شھر.ًا 213<br />&bull; یحُفظ بعیدًا عن مرأى ومتناول الأطفال . 214<br />&bull; احتفظ بالمحقنة في العلبة الكرتونیة الخارجیة (في عبوتھا البلاستیكیة المغلقة) لحمایتھا من الضوء . 215<br />&bull; لا تستخدم ھذا الدواء إذا لاحظت أن المحلول غائم أو بھ رواسب . 216<br />&bull; لا تتخلص من أي أدویة في میاه الصرف الصحي أو النفایات المنزلیة . 217<br />اسأل الصیدلي عن كیفیة التخلص من الأدویة التي لم تعد تستخدمھا. ستساعد ھذه التدابیر على حمایة البیئة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعال ة 225 الغلوبولین المناعي البشري المضاد ل د . 226 یحتوي روفیلاك 300 على 60 ملغ كحد أقصى من بروتینات البلازما البشریة لكل محقنة معبأة مسبقًا (2 مل)، منھا 20 ملغ من . IgG 227 الألبومین كمثبت. تتكون نسبة 95% على الأقل من بروتینات البلازما الأخرى منأقل من حد الكشف البالغ 10 میكروغرام/محقنة معبأة مسبقاً (2 مل) . A 228 محتوى الغلوبولین المناعي229 السواغا ت 230 محقنة ألبومین بشري 20 ملغ/معبأة مسبقاً (2 مل، كمثبت)، جلیسین، كلورید الصودیوم بحد أقصى 0.5 مللي مول من الصودیوم لكل 231 محقنة معبأة مسبقًا)، حمض الخلیك، ماء للحقن .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>یتوفر روفیلاك 300 في محقنة زجاجیة معبأة مسبقاً مع 2 مل من محلول معقم جاھز للاستخدام، یحتوي على 1500 وحدة دولیة 300 میكروغرام) من الغلوبولین المناعي المضاد ل د . ) 234235 روفیلاك 300 ھو محلول غلوبولین مناعي صافي عدیم اللون إلى أصفر باھت. المحلول مفرط التوتر قلیلاً .</p><p>236 یتوفر روفیلاك في عبوات فردیة تحتوي على محقنة معبأة مسبقًا وإبرة حقن واحدة، وكلاھما معبأ في شریط واحد (حاویة بلاستیكیة شفافة 237 مغلقة برقاقة ورقیة) .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>CSL Behring AG 240Wankdorfstr. 10 2413014 Bern 242243 سویسر ا<br />244245 للإبلاغ عن أي أثر جانبي (آثار جانبیة) : 246 المملكة العربیة السعودیة : :(NPC) 247 المركز الوطني للیقظة الدوائیة 248 مركز الاتصال بالھیئة السعودیة للغذاء والدواء: 19999 npc.drug@sfda.gov.sa :249 البرید الإلكتروني https://ade.sfda.gov.sa :250 الموقع الإلكتروني<br />251</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            دیسمبر 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rhophylac 300
Human anti-D immunoglobulin.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active substance
Human anti-D immunoglobulin.
Rhophylac 300 contains a maximum of 60 mg human plasma proteins per pre-filled syringe
(2 mL), of which 20 mg is albumin as stabiliser. At least 95% of the other plasma proteins consist
of IgG.
The IgA content is below the detection limit of 10 mcg/pre-filled syringe (2 mL).
Excipients
Human albumin 20 mg/pr-efilled syringe (2 mL, as stabiliser), glycine, sodium chloride maximum
of 0.5 mmol sodium per pre-filled syringe), acetic acid, water for injections.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection for intravenous and intramuscular use.
A 2°ml pre-filled syringe contains 300 mcg (1500 IU) of human anti-D immunoglobulin G (IgG).
Rhophylac 300 is a clear, colourless to pale yellow immunoglobulin solution. The solution is
slightly hypertonic.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A) Prophylaxis of Rh(D) immunisation in Rh(D) negative women:<br />Anti-D immunoglobulin is used to prevent haemolytic disease of the newborn caused by Rh(D)<br />antibodies. In Rh(D) negative women, sensitisation may be due to fetal Rh(D) positive red blood<br />cells entering the maternal circulation.<br />Rhophylac is administered with the following constellations:<br />a) Routine antepartum prophylaxis<br />In Rh(D) negative women (including partial D) for routine antepartum prophylaxis in the<br />28th to the 30th week of pregnancy for the prevention of Rh(D) immunisation as a result<br />of fetomaternal transfusions occurring spontaneously in the last trimester ( fetomaternal<br />haemorrhage (FMH)).</p><p>In the event of complications during pregnancy in Rh(D) negative women (including partial<br />D):<br />􀁸 Procedures during pregnancy, for example invasive prenatal diagnostic investigations<br />(such as amniocentesis, chorionic villus sampling, cordocentesis/fetal blood sampling)<br />or intrauterine procedures (such as insertion of shunts, embryo reduction), external<br />cephalic version, and therapeutic abortion.<br />􀁸 Incidents during pregnancy, such as antepartum haemorrhage, spontaneous abortion,<br />ruptured fallopian tube pregnancy, ectopic pregnancy, stillbirth, intrauterine death and<br />abdominal trauma.<br />b) For postpartum prophylaxis if the mother is Rh(D) negative (including partial D) and the<br />child is Rh(D) positive.</p><p>B) Prophylaxis of Rh(D) immunisation in Rh(D) negative persons after incompatible transfusions<br />of Rh(D) positive blood or blood products containing Rh(D) positive red blood cells.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5 Dosage / Administration<br />Rhophylac may be administered both intravenously and intramuscularly.<br />The dose of anti-D immunoglobulin should be determined according to the level of exposure to<br />Rh(D) positive red blood cells (RBCs) and based on the knowledge that 0.5 mL of packed Rh(D)<br />positive RBCs or 1 mL of Rh (D) positive blood is neutralised by approximately 10 mcg (50 IU) of<br />anti-D immunoglobulin.<br />The following recommended dosages are based on the clinical studies performed with<br />Rhophylac. For specific study details, see section &ldquo;Pharmacodynamics&rdquo;. The recommended<br />dosages and official guidelines for the intramuscular and intravenous use of human anti-D<br />immunoglobulin should be followed.<br />To ensure traceability of biological medicinal products, it is recommended that the trade name<br />and batch number should be documented for each treatment.</p><p>Dosage<br />A) Prophylaxis of Rh(D) immunisation in Rh(D) negative women (including partial D):<br />a) Routine antepartum prophylaxis:<br />A dose of 300 mcg (1500 IU), administered in the 28th to the 30th week of pregnancy by<br />intravenous or intramuscular injection, is recommended.<br />CSL Behring<br />Rhopylac&reg;<br />MMM/MEA/EN, Rev.: December 2020 / CCDS update V2.0 &amp; 3.0<br />Should the need for antepartum prophylaxis not be established until after the 30th week of<br />pregnancy, Rhophylac should not be withheld but administered as quickly as possible.<br />Prophylaxis after complications during pregnancy:<br />􀁸 Procedures and incidents: 300 mcg (1500 IU) should be given intravenously or<br />intramuscularly as soon as possible and no later than 72 hours after the complication<br />has occurred. Rhophylac should still be administered as quickly as possible even if<br />more than 72 hours have elapsed. The dose of anti-D IgG should then be repeated<br />every 12 weeks until the birth.<br />􀁸 Invasive prenatal diagnostic investigations: Irrespective of the time of the procedure,<br />300 mcg (1500 IU) should be given intravenously or intramuscularly as soon as<br />possible and no later than 72 hours after the procedure.</p><p>b) Postpartum prophylaxis:<br />300 mcg (1500 IU) should be given intravenously or intramuscularly as soon as possible<br />and no later than 72 hours after the birth. Rhophylac should be administered as quickly as<br />possible even if the 72 hours have elapsed.<br />In cases of known or suspected excessive FMH, the number of fetal red blood cells in the<br />mother&rsquo;s circulation should be determined using the Kleihauer-Betke test or by another suitable<br />test method (e.g. by flow cytometry). If excessive transplacental FMH5(&gt;4 mL Rh(D) positive fetal<br />red blood cells) is detected, additional Rhophylac (10 mcg (50 IU) per 0.5 mL Rh(D) positive fetal<br />red blood cellsor per 1 mL RhD positive fetal whole blood) should be injected, preferably<br />intravenously. If no test is available and excessive FMH cannot be excluded, an additional dose<br />of 300 mcg (1500 IU) should be injected.<br />B) Incompatible transfusions:<br />The dose is 10 mcg (50 IU) anti-D Immunoglobulin per 0.5 mL (RhD) positive packed red blood<br />cells or 1 mL transfused Rh(D) positive whole blood. Intravenous administration is recommended<br />in order to achieve immediate plasma availability. In the event of intramuscular use, large doses<br />should be given in divided doses over several days. A total dose of 3000 mcg (15,000 IU) will be<br />sufficient, even if more than 300 mL Rh(D) positive whole blood or 150 mL Rh(D) positive packed<br />red blood cells have been transfused. Given the possible risk of haemolysis, it is generally<br />recommended not to exceed a dose of 3000 mcg (15,000 IU).<br />The dose recommendations for prevention of Rh(D) isoimmunisation are summarised in the<br />following table:</p><p>Indication Timing of Administration Dose<br />Routine antepartum prophylaxis:<br />At 28 to 30 weeks of<br />pregnancy<br />300 mcg (1500 IU) as single<br />dose<br />Antepartum prophylaxis<br />following complications of<br />pregnancy<br />Procedures and incidents:<br />Invasive prenatal diagnostic<br />investigations:<br />Within 72 h of complication<br />Within 72 h of procedure<br />300 mcg (1500 IU) as single<br />dose<br />300 mcg (1500 IU) as single<br />dose<br />Postpartum prophylaxis: Within 72 h of birth 300 mcg (1500 IU) as single<br />dose<br />Massive fetomaternal<br />haemorrhage (&gt;4 mL) Within 72 h of complication<br />300 mcg (1500 IU) as single<br />dose plus:<br />&bull; 10 mcg (50 IU) per<br />0.5 mL transfused Rh(D)<br />positive fetal red blood cells<br />or<br />&bull; 10 mcg (50 IU) per 1 mL<br />transfused Rh(D) positive fetal<br />whole blood<br />Incompatible transfusions Within 72 h of exposure<br />&bull; 10 mcg (50 IU) per 0.5 mL<br />Rh(D) positive packed red<br />blood cells or<br />&bull; 10 mcg (50 IU) per 1 mL<br />Rh(D) transfused Rh(D)</p><p>Children and adolescents<br />Since the dosage in the event of incompatible transfusions depends on the volume of the Rh(D)<br />positive blood or Rh(D) positive red blood cells, the recommended dose for children and<br />adolescents (0-18 years) is no different to that for adults. The appropriate dose should, however,<br />be determined in consultation with a transfusion specialist.<br />Mode of administration<br />Rhophylac 300 is ready for use and should be at room or body temperature when administered.<br />Rhophylac 300 can be given either by slow intravenous or by slow intramuscular injection. In<br />patients with coagulation disorders in whom intramuscular administration is contraindicated,<br />Rhophylac 300 should be injected intravenously. If large doses (&gt; 5 mL) are to be administered<br />intramuscularly, it is advisable to give them in divided doses at different administration sites.<br />It is recommended that patients are observated for a period of at least 20 minutes after<br />administration.<br />Overweight patients<br />Intravenous administration is recommended for patients with a body mass index (BMI) of 􀂕 30<br />(see also section &ldquo;Warnings and precautions&rdquo;).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to human immunoglobulins.
Hypersensitivity to any of the excipients (see section “Composition”).
Intramuscular administration is contraindicated in persons with severe thrombocytopenia or other
coagulation system disorders.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Postpartum prophylaxis is given to the mother. Anti-D immunoglobulin should not be given to the<br />neonate.<br />The product is not intended for administration to Rh(D) positive individuals or for persons who<br />have already been immunised against Rh(D) antigen.<br />Rhophylac contains less than 1 mmol sodium (23 mg) per pre-filled syringe, that is to say<br />essentially &ldquo;sodium free&rdquo;.<br />The maximum recommended dose is 3000 mcg (15,000 IU). This corresponds to 20 mL<br />Rhophylac and thus 5 mmol or 115 mg sodium, equivalent to 6% of the WHO recommended<br />maximum daily dietary intake of 2 g sodium for an adult.</p><p>Hypersensitivity<br />Anti-D immunoglobulin may cause allergic reactions even in patients who have tolerated earlier<br />administrations. It is therefore recommended that patients are informed about the early signs of a<br />hypersensitivity reaction. Such signs may be hives, generalized urticaria, tightness in the chest,<br />dyspnoea, drop in blood pressure, and anaphylaxis. The treatment needed should be tailored to<br />the type and severity of the adverse reaction. If symptoms of shock occur, the current medical<br />guidelines on the treatment of shock should be followed. Administration should be stopped<br />immediately if allergic or anaphylactic reactions occur.<br />The concentration of IgA in Rhophylac 300 is below the detection limit of 5 mcg/mL. However, it<br />cannot be ruled out that the product contains traces of IgA. Persons with IgA deficiency may<br />develop antibodies to IgA and may react to the administration of blood components containing<br />IgA with anaphylactic symptoms. It is the doctor&rsquo;s responsibility to weigh up the benefit of<br />treatment with Rhophylac 300 against the possible risk of a hypersensitivity reaction.<br />Haemolytic reactions<br />Patients treated with large doses of anti-D immunoglobulin after an incompatible transfusion<br />should be monitored on the basis of clinical and laboratory parameters because of the risk of a<br />haemolytic reaction.<br />Obesity (adiposity)<br />There are reports that there is a risk of a lack of effectiveness with the intramuscular<br />administration of Rhophylac to patients with a body mass index (BMI) of 􀂕􀀖􀀓􀀑􀀃For this reason,<br />intravenous administration is recommended for patients with a BMI of 􀂕􀀖􀀓􀀑<br />Information on Safety with respect to transmissible agents<br />Standard measures to prevent infections resulting from the use of medicinal products prepared<br />from human blood or plasma include the selection of donors, screening of individual donations<br />and plasma pools for specific infection markers, and in inclusion of effective manufacturing steps<br />for the inactivation/ elimination of viruses. Nevertheless, when medicinal products prepared from<br />human blood or plasma are administered, the possibility of transmitting infectious agents cannot<br />be totally excluded. This also applies to previously unknown or emerging viruses and other<br />pathogens.<br />The procedures used are regarded as effective against enveloped viruses such as human<br />immunodeficiency virus (HIV), hepatitis B virus (HBV) and heptatitis C virus (HCV). They may be<br />of limited value with non-enveloped viruses such as hepatitits A virus (HAV) and parvovirus B19.<br />Clinical experience shows that hepatitis A or parvovirus B19 infections are not transmitted by<br />immunoglobulins, and it is also assumed that the antibody content makes an important<br />contribution to viral safety.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Live-attenuated virus vaccines<br />After the administration of anti-D immunoglobulin, an interval of at least 3 months must elapse<br />before vaccination with live virus vaccines (for example, against measles, mumps, rubella or<br />varicella) since otherwise the vaccination might not be successful. If anti-D immunoglobulin is<br />administered within 2-4 weeks after vaccination with a live virus vaccine, it may impair the<br />effectiveness of the vaccination.<br />Interference with serological determinations<br />With serological testing after the administration of immunoglobulins, it must be borne in mind that<br />the transient rise in various passively transmitted antibodies in the patient&rsquo;s blood may result in<br />false positive results.<br />Determinations of blood group and antibodies in neonates, including the Coombs&rsquo; or antiglobulin<br />test, are substantially affected by the administration of anti-D immunoglobulin, i.e. the<br />administration of anti-D immunoglobulin may give a positive direct Coombs&rsquo; test in the neonate.<br />However, such a result does not indicate the presence of rhesus incompatibility.<br />Rhophylac 300 may contain antibodies of other red blood cell antigens, such as anti-A, anti-B,<br />Rh(C), and Rh&euro; antibodies that can be detected by sensitive serological test methods.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This product is used during pregnancy and postpartum period. There are no known negative<br />effects on the course of pregnancy and/or the neonate.<br />This medicinal product can be used during lactation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence of any adverse effects on the ability to drive or to operate machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following adverse drug reactions have been reported from clinical studies with 592 patients<br />and are based on analyses of post-marketing data. The list below is presented according to the<br />MedDRA system organ classes (SOC and Preferred Term (PT)). The following frequency<br />convention is used: very common 􀀋􀂕􀀃􀀔􀀒􀀔􀀓􀀌􀀏􀀃common 􀀋􀂕􀀃􀀔􀀒􀀔􀀓􀀓􀀃and &lt;1/10), uncommon 􀀋􀂕􀀃􀀔􀀒􀀔􀀓􀀓􀀓􀀃<br />and &lt;1/100), rare 􀀋􀂕􀀃􀀔􀀒􀀔􀀓,000 and &lt;1/1000), very rare (&lt; 1/10,000).</p><p>Immune system disorders:</p><p>Rare: Hypersensitivity reaction, anaphylactic shock<br />Nervous system disorders:<br />Uncommon: Headache<br />Cardiac disorders:<br />Rare: Tachycardia<br />Vascular disorders:<br />Rare: Drop in blood pressure<br />Respiratory, thoracic and mediastinal disorders:<br />Rare: Dyspnoea<br />Gastrointestinal disorders:<br />Rare: Nausea, vomiting<br />Skin and subcutaneous tissue disorders:<br />Uncommon: Skin reaction, erythema, pruritus<br />Musculoskeletal and connective tissue disorders:<br />Rare: Arthralgia<br />General disorders and administration site conditions:<br />Uncommon: Fever, malaise, chills<br />Rare: At the injection site: swelling, pain, erythema, induration, warmth, pruritus, rash<br />There are spontaneous reports of severe intravascular haemolysis after the intravenous use of<br />anti-D in Rh(D) positive patients with primary immune thrombocytopenia (ITP) (off label use).<br />Cases of haemolysis resulting in death have been reported. The exact frequency of this adverse<br />effect is not known.<br />If anti-D immunoglobulins are administered intramuscularly, local pain and sensitivity may occur<br />at the injection site.<br />CSL Behring<br />Rhopylac&reg;<br />MMM/MEA/EN, Rev.: December 2020 / CCDS update V2.0 &amp; 3.0<br />Information about virus safety: see section &ldquo;Warnings and precautions&rdquo;.<br />Reporting suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is very<br />important. It allows continued monitoring of the benefit/risk ratio of the medicinal product.<br />Healthcare professionals are requested to report any suspected new or serious adverse reaction<br />through.<br />Saudi Arabia:<br />The National Pharmacovigilance Centre (NPC):<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa<br />Sultanate of Oman:<br />Department of Pharmacovigilance &amp; Drug Information<br />Directorate General of Pharmaceutical Affairs &amp; Drug Control<br />Ministry of Health, Sultanate of Oman<br />Phone Nos. 22357687 / 22357686<br />Fax: 22358489<br />Email: dg-padc@moh.gov.om<br />Website: www.moh.gov.om<br />United Arab Emirates:<br />Pharmacovigilance &amp; Medical Device section<br />P.O.Box: 1853<br />Tel: 80011111<br />Email: pv@mohap.gov.ae<br />Drug Department<br />Ministry of Health &amp; Prevention<br />Dubai, UAE<br />Other GCC States:<br />Please contact the relevant competent authority.<br />Algeria:<br />http://www.cnpm.org.dz/index.php<br />Tunisia:<br />effets.indesirables@rns.tn or www.pharmacovigilance.rns.tn<br />CSL Behring<br />Rhopylac&reg;<br />MMM/MEA/EN, Rev.: December 2020 / CCDS update V2.0 &amp; 3.0<br />Egypt:<br />The Egyptian Pharmaceutical Vigilance Center (EPVC)<br />Email: pv.followup@edaegypt.gov.eg<br />Website: www.edaegypt.gov.eg<br />Hotline:15301<br />Jordan:<br />Email: jpc@jfda.jo<br />JFDA reporting link on JFDA website www.jfda.com: https://primaryreporting.who-umc.org/JO<br />Tel: +962-6-5632000<br />Iraq<br />Please Contact The Iraqi Pharmacovigilance center<br />Mobile: 07807820490<br />E-mail: iraqiphvc@moh.gov.iq<br />Website: http://tec-moh-com/</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No data on overdose are available. The consequences of overdose are not known.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code: J06B B01<br />Pharmacotherapeutic group: immune sera and immunoglobulins: anti-D (Rh) immunoglobulin<br />Rhophylac 300 contains specific IgG antibodies to the Rh(D) antigen of human red blood cells.<br />Rhophylac 300 is prepared from pooled human plasma. The starting material is the plasma of<br />Rh(D) negative persons who have been immunised in the past through a specific incompatible<br />pregnancy (women) or with Rh(D) positive red blood cells.<br />The immunoglobulin contained in Rhophylac 300 is obtained by ion-exchange chromatography.<br />The method is extremely gentle and prevents spontaneous complement activation; for this<br />reason, the product is suitable for intravenous use. This process does not alter the binding<br />properties of the immunoglobulin; when binding to the Rh(D) antigen it therefore retains all its<br />biological functions.<br />The particular isolation method leads to the specific concentration of the desired anti-D<br />immunoglobulins.<br />Mechanism of action<br />CSL Behring<br />Rhopylac&reg;<br />MMM/MEA/EN, Rev.: December 2020 / CCDS update V2.0 &amp; 3.0<br />In Rh(D) negative mothers, anti-D immunoglobulin prevents the formation of antibodies to fetal<br />Rh(D) positive red blood cells that have entered the circulation. The mechanism probably via<br />binding of the anti-D antibodies to the Rh(D) antigen of Rh(D) positive red blood cells and<br />subsequent degradation of the resulting complex by cells of the monocytic phagocyte system,<br />mainly in the spleen.<br />Standard doses of 300 mcg administered postpartum prevent 90% of all cases of sensitisation in<br />the Rh(D) system. The protective effect of postpartum prophylaxis is increased to 99% by<br />additional antepartum prophylaxis.<br />Pharmacodynamics properties<br />In clinical studies in healthy male Rh(D) negative test subjects have shown that both the<br />intravenous and the intramuscular administration of Rhophylac 300 leads to the efficient removal<br />of Rh(D) positive red blood cells from the circulation. Compared with intravenous administration,<br />the elimination of Rh(D) positive red blood cells is delayed on intramuscular administration, since<br />the anti-D immunoglobulin first has to be absorbed from the injection site.<br />Clinical efficacy<br />It has shown in clinical studies that the ante- and postpartum administration of Rhophylac 300<br />effectively prevents Rh(D) immunisation in Rh(D) negative women.<br />In two clinical studies, Rhophylac 300 was administered to Rh(D) negative women in the 28th<br />week of pregnancy and within 72 hours after the birth of an Rh(D) positive child. 206 per-protocol<br />subjects received the antepartum dose of Rhophylac 300 intravenously and 202 per-protocol<br />subjects received it intramuscularly. The post- and antepartum method of administration was the<br />same In more than 99% of cases.<br />6-11 months after the birth, 256 of the 278 women who gave birth to an Rh(D) positive child were<br />available for follow-up. Anti-D antibodies could not be detected in any of the women, which<br />suggest that no Rh(D) immunisation occurred.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Anti-D immunoglobulin is available immediately, after intravenous injection, whereas measurable<br />serum anti-D IgG levels are achieved only after about 4 hours following intramuscular injection.<br />Distribution<br />The maximum serum anti-D IgG concentration is reached after 5 days on average. After 2-3<br />weeks, the serum levels converge, so that there is no longer any difference between the two<br />routes of administration.<br />Metabolism</p><p>IgG and IgG complexes are broken down in the cells of the reticuloendothelial system.<br />Elimination<br />The average half-life of anti-D IgG in pregnant women is 17 days.<br />Kinetics in special patient groups<br />To date there is no evidence that the pharmacokinetic properties of anti-D IgG are altered in<br />kidney disease or with increasing age.<br />The biological half-life depends on the plasma level of IgG, i.e. in patients with<br />hypogammaglobulinaemia it may increase to 70 days, in those with hypergammaglobulinaemia it<br />may be reduced to 11 days.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immunoglobulins are normal constituents of the human body. Single-dose toxicity studies are not<br />valid, since higher doses lead to protein overloading in animals. Repeated-dose toxicity tests and<br />embryofetal studies cannot be carried out, since they lead to the development of and interference<br />with antibodies. This product&rsquo;s effects on the immune system of the neonate have not been<br />investigated.<br />Since there is no clinical evidence of oncogenic or mutagenic effects of immunoglobulins,<br />experimental studies are not necessary, particularly in heterologous species.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Incompatibilities<br />Rhophylac 300 must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf-life
36 months
Do not use the product after the printed expiry date (“EXP”).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Special precautions for storage<br />Store in a refrigerator at +2 to +8 C. Do not freeze. Keep out of the reach of children. Keep the<br />pre-filled syringe (with the blister unopened) in the outer carton in order to protect the contents<br />from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Instructions for handling<br />The solution should be clear or slightly opalescent. Do not use solutions that are cloudy or<br />contain deposits.<br />CSL Behring<br />Rhopylac&reg;<br />MMM/MEA/EN, Rev.: December 2020 / CCDS update V2.0 &amp; 3.0<br />Rhophylac 300 is intended to be single use only; unused product or surplus material should be<br />disposed of in accordance with local regulations.<br />17 Marketing authorization number:<br />Saudi Arabia: 0606222136<br />Egypt: EGY/BP/October.2016/00122/01<br />Algeria: 14/12J 171/485<br />Tunisia: 13813011<br />Lebanon: 23859/07<br />Kuwait: 4932/Jul 03<br />UAE: 4537-5684-3<br />Oman: D04800A<br />Yemen: 0010436<br />Jordan: 15/ 􀤐 􀤟- B.P/2021<br />Iraq: 17-564</p><p>18 Packs<br />2 ml (300 􀈝􀁊􀀌􀀃solution in a pre-filled syringe with an injection needle (B)<br />ListI &ndash; Prescription only medicines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CSL Behring AG
Wankdorfstr. 10
CSL Behring
Rhopylac®
MMM/MEA/EN, Rev.: December 2020 / CCDS update V2.0 & 3.0
3014 Bern
Switzerland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>